LMSSIO

Abbreviated New Drug Application Claim

An Abbreviated New Drug Application (ANDA) Claim arises when there is a dispute or legal challenge related to the submission or approval of an ANDA, which allows for the marketing of a generic drug that demonstrates bioequivalence to an already approved brand-name drug. This claim can involve issues of patent infringement, exclusivity rights, or regulatory compliance.

IRI
http://lmss.sali.org/RCsgBzhoO77TRUSo5O757qS
Branch
Objectives

Also known as

ANDA Claim, ANDA Dispute Claim, Bioequivalence Application Claim, Generic Drug Application Claim, Generic Medicine Application Claim

Ancestry paths

Generated from sali-legal/LMSS at 3f9ac0c9357b (2026-03-10). JSON